FLIP: Fiducial Localization and Individualized Radiotherapy -Prostate Cancer

Sponsor

University Health Network, Toronto (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT00789607

Collaborator

Princess Margaret Hospital, Canada (Other)

Enrollment

Location

Arms

168

Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This purpose of this study is designed to compare two types of images; magnetic resonance imaging (MRI) and Trans-Rectal Ultrasound (TRUS) to see which one performs more accurately for the image-guided insertion of Fiducial Markers(FMs) within the tumour. Though effective for guiding FM placement at the poles of the prostate gland due to excellent visualization of the prostatic boundaries, TRUS may not be ideally suited for marking the GTV. Conventional TRUS is neither sufficiently sensitive nor specific for accurate visualization of intra-prostatic tumor. A new interventional MRI technique enables needle guidance to the gross tumour Volume (GTV) for FM placement. It is of particular importance that both techniques be evaluated to enable which one is more effective so that it can be implemented in the designs of future trials involving dose-escalation to prostate.

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer	Device: Transrectal APT Device or Transperineal Device will be used Device: TRUS probe	N/A

Detailed Description

The success of dose escalation strategies in prostate cancer over the last decade has relied on high accuracy in target delineation, localization and radiation delivery. Improved biochemical control with acceptable levels of toxicity (specifically rectal) has been achieved by stringently monitoring the location of the prostate during the course of radiation treatment. Studies in the early 1990's demonstrated that daily bony alignment was a poor surrogate for prostate gland location. Since then, various strategies have been devised to localize the prostate precisely during treatment. Of these, Transrectal Ultrasound (TRUS)-guided gold fiducial marker (FM) insertion and x-ray imaging of markers has been a broadly successful approach. TRUS guidance has been used for fiducial marker insertion within the prostate since 1985 in various centers throughout the world and has also been a standard practice in PMH since 1997 in men undergoing radical external beam radiotherapy. A retrospective comparative study of 106 patients evaluating the relative accuracy of endorectal MRI and TRUS in detecting the location of tumor reported an improved performance of endorectal MRI especially in the base and midgland regions. Over the last few years, mounting experience in the interpretation of prostate MRI, and addition of physiologic imaging sequences has further improved the performance of MRI in detecting and localizing the GTV.

Study Design

Study Type:

Interventional

Actual Enrollment :

17 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Fiducial Localization and Individualized Radiotherapy in Prostate Cancer (FLIP)

Study Start Date :

Jun 1, 2008

Actual Primary Completion Date :

Jun 1, 2017

Anticipated Study Completion Date :

Jun 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: MRI-guided FM	Device: Transrectal APT Device or Transperineal Device will be used Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
Active Comparator: TRUS-guided FM	Device: TRUS probe Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.

Arm

Intervention/Treatment

Active Comparator: MRI-guided FM

Device: Transrectal APT Device or Transperineal Device will be used

Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position

Active Comparator: TRUS-guided FM

Device: TRUS probe

Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.

Outcome Measures

Primary Outcome Measures

To compare the performance of MRI and TRUS images in guiding the insertion of a fiducial marker within the Gross Target Volume (GTV) [5 years]

Secondary Outcome Measures

To measure the needle targeting accuracy of the MRI-guided technique. [5 years]
To validate the accuracy of identifying the GTV on MRI. [5 years]
To evaluate MRI methods for the characterization of tissue oxygenation. [5 years]
To evaluate the effect of neoadjuvant hormone therapy on tissue oxygenation. [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

≥ 18 years old
ECOG status ≤ 1
High risk localized cancer planned for RT under FM guidance
Gleason > 7, PSA > 20, Clinical stage ≥ T3
patients(pts) must give written informed consent

Exclusion Criteria:

pts > 136 kg or > 60 cm in girth
Pts with pacemakers, cerebral aneurysm clips, shrapnel injury or devices not compatible with MRI.
pts with severe claustrophobia
pts with bleeding diathesis and anticoagulative therapy that cannot be ceased prior to needle procedures.
Contraindications to endorectal probe, surgically absent rectum, severe hemorrhoids or previous colorectal surgery.
Latex Allergy